Mr. Gionco, age 52, joined the Company in February 2006 as Vice President of Corporate Finance and Controller, and served as the Company's Group Vice President - Chief Financial Officer & Treasurer from February 2009 until September 2011, and Group Vice President - Finance from September 2011 to May 2012. From August 2004 to February 2006, Mr. Gionco served as Acting Chief Financial Officer/Director of Finance and Controller of Odyssey Pharmaceuticals, a specialty pharmaceuticals company. From July 2003 through August 2004, he served as the Director of Finance for Progenics Pharmaceuticals. Mr. Gionco has spent more than 21 years in the pharmaceutical industry in various audit, corporate accounting, financial planning, finance and controller roles at several pharmaceutical companies, including Medco Health Solutions, Inc. and Merck & Co. In addition, Mr. Gionco has seven years of financial auditing experience with Edward Isaacs & Company, a public accounting firm that was acquired in 2000 by McGladrey & Pullen. Mr. Gionco holds a B.S. in Accounting from Fairleigh Dickinson University and an MBA from Rutgers University.

Mr. Gionco is entitled to an annual base salary of $300,150 and a target annual bonus of 40% of his bas salary. Additionally, the Company and Mr. Gionco are parties to an Amended and Restated Employment Agreement (the "Agreement"), pursuant to which, if the Company terminates Mr. Gionco's employment at any time for any reason other than cause, or if Mr. Gionco terminates his employment for good reason, Mr. Gionco will be entitled to receive his base salary and benefits as set forth in the Agreement for a period of 52 weeks. In the event Mr. Gionco's employment is terminated due to disability, he will be entitled to a pro rata portion of his short-term equity incentive award for the year in which the disability occurred.

The terms "cause", "good reason" and "disability" are defined in the Agreement and incorporated herein by reference. This summary of the Agreement is qualified in its entirety by the terms and conditions of the Agreement, which was filed as Exhibit 10.1 on the Company's Current Report on Form 8-K on February 19, 2009.